Kaitlyn Bader is the senior editor of Dermatology Times® and joined the MJH Life Sciences team in June 2022. She attended Otterbein University in Westerville, Ohio, and earned a Bachelor of Arts degree in literary studies with minors in creative writing and film studies. Prior to health care news, Kaitlyn worked in industrial marketing. She enjoys cooking, reading, and tending to her house plants.
The Weekly Roundup: December 18-22
December 23rd 2023ICYMI, this week we had articles about vitiligo onset following COVID-19 vaccination, a Revolutionzing Vitiligo interview with Nanette Silverberg, MD, the FDA approval of Filsuvez for the treatment of partial thickness wounds related to dystrophic junctional and epidermolysis bullosa, and more.
FDA Approves Historic Roflumilast Foam 0.3% For Seborrheic Dermatitis
December 15th 2023Roflumilast foam 0.3% is the first FDA-approved drug for seborrheic dermatitis with a new mechanism of action in over 2 decades. Christopher Bunick, MD, PhD; Shawn Kwatra, MD; and Peter Lio, MD, share expert insights.
The Weekly Roundup: November 26-December 1
December 2nd 2023ICYMI, this week we had articles about the FDA granting priority review of Abeona's pz-cel BLA for recessive DEB, end-of-the-month highlights from the November issue and supplement of Dermatology Times, the FDA accepting Arcutis' sNDA of roflumilast cream 0.15% for AD, and more.